Vol 9 Issue 3

Download PDF

Featuring

Issue Spotlight: Vector bioprocessing & raw materials
Other articles
Webinars

Vector bioprocessing & raw materials

Guest Editor:

Andrew D Tustian, Senior Director, Preclinical Manufacturing and Process Development at Regeneron Pharmaceuticals, Inc.

Innovator Insight

Determination of physical viral vector titer in process development & QC for cell & gene therapy

Daniel Forsström, John Chappell

4 May

Read

Sustainable plasmid DNA strategies, achieving streamlined secure supply to clinic & commercialization

Andrew Frazer, Amanda Weiss

26 April

Read

Commentary

Opportunities to implement continuous processing in production of recombinant adeno-associated viral vectors

G Thakur, S Mink, H Bak et al.

6 June

Read

Interview

Exploring the evolution of upstream & downstream viral vector processing

Francesca Vitelli

3 April

Read

Expert Roundtable

Driving the expansion of mRNA into the therapeutic sphere

A Becerra, A Kuhn, M Kurtoglu

10 April

Read

Viewpoint

Standardizing success: paving the way for streamlined viral vector manufacturing in gene therapy

Raquel Martín-Ibáñez

26 April

Read

Setting up a one-stop shop: bringing viral vector manufacturing in-house

Danielle Steele

17 April

Read

Transfection optimization for AAV production

Peter Boyce

3 April

Read

Infographic

Plasmid DNA manufacturing and analytics: INFOGRAPHIC

29 July

Read

Journal articles

Innovator Insight

Challenges of developing anti-drug antibody & concentration (PK or PD) assays for liposomal transgene enzymes on an automated immunoassay platform

Issa Jyamubandi

1 April

Read

Interview

Expert Roundtable

Accelerating cancer therapies development: the importance of platform, process, and partnership

W Swaney, J Shyu, N Tyagi

22 April

Read

FastFacts

Advancing AAV gene therapy development for the treatment of neurodegenerative diseases

Carina Peritore

21 April

Read

Viewpoint

Funding the future: cell & gene therapy development

Nick Meyers, Neil Fish

28 March

Read

The fast and the curious – optimized development of high performing AAV vectors

Dirk Grimm, David Schaffer

2 March

Watch

Advancing the purification of VSV-G pseudotyped lentiviral vectors by using affinity chromatography

Pim Hermans, Frank Detmers

7 March

Watch

Case studies: Successful scale-up of upstream viral vector processes using adherent and suspension platforms

Samir Acharya, Denis Kole

14 March

Watch

Navigating evolving regulatory CMC guidance in the AAV gene therapy field

Y Zhi, C Le Bec, M Brewer et al.

22 March

Watch

Scalable production in single-use bioreactors

Jonathan Zmuda PhD, Premkumar Jayaraman PhD

29 March

Watch

Chromatographic modalities, buffer selection and other considerations for enrichment of AAV product

Rok Žigon

5 April

Watch

De-risking lentiviral vector production using a robust, scalable, suspension-based platform

Jimmy Xin, Poornima Manavalan

11 April

Watch

Skip the hassle for AAV and AdV empty/full and titer data with Stunner

Nelis Denys

12 April

Watch

Development of anti-AAV assay for detection of pre-existing AAV immunity

Zhe Liu, John Chappell

18 April

Watch

Analyzing full and empty AAV capsid ratio in less than 5 minutes

Åsa Hagner-McWhirter PhD

19 April

Watch

Large-scale genome editing of primary human natural killer (NK) cells: A quest toward manufacture of clinically relevant CAR NK cells

Deepak Kumar

20 April

Watch

High-throughput process & analytical platforms to accelerate gene therapy scale-up

P Starremans PhD, K Warrington PhD, N Jesuraj PhD

25 April

Watch

Environmental monitoring: optimizing microbial control in cell and gene therapy workflows

Nico Chow

27 April

Watch

Manufacturing and testing a clinical-grade AAV vector: from concept to clinic

Chris Edwards, James Cody

4 May

Watch

Future-proof your AAV process with a complete producer cell line – just induce and grow

Dovile Gruzdyte

25 May

Watch

CELL AND GENE THERAPY INSIGHTS

April 2023 Issue

Vol 9 Issue 3

Featuring

SPOTLIGHT

Vector bioprocessing & raw materials

Innovator Insight

Determination of physical viral vector titer in process development & QC for cell & gene therapy

Sustainable plasmid DNA strategies, achieving streamlined secure supply to clinic & commercialization

Commentary

Opportunities to implement continuous processing in production of recombinant adeno-associated viral vectors

Interview

Exploring the evolution of upstream & downstream viral vector processing

Expert Roundtable

Driving the expansion of mRNA into the therapeutic sphere

Viewpoint

Standardizing success: paving the way for streamlined viral vector manufacturing in gene therapy

Setting up a one-stop shop: bringing viral vector manufacturing in-house

Transfection optimization for AAV production

Infographic

Plasmid DNA manufacturing and analytics: INFOGRAPHIC

Journal articles

Innovator Insight

Challenges of developing anti-drug antibody & concentration (PK or PD) assays for liposomal transgene enzymes on an automated immunoassay platform

Interview

New directions and evolving challenges in the CAR-T cell therapy space

Key considerations & development of regulatory guidance in CMC

A payment innovation framework to meet the urgent need in advanced therapies

Expert Roundtable

Accelerating cancer therapies development: the importance of platform, process, and partnership

FastFacts

Advancing AAV gene therapy development for the treatment of neurodegenerative diseases

Viewpoint

Funding the future: cell & gene therapy development

Webinars

The fast and the curious – optimized development of high performing AAV vectors

Advancing the purification of VSV-G pseudotyped lentiviral vectors by using affinity chromatography

Case studies: Successful scale-up of upstream viral vector processes using adherent and suspension platforms

Navigating evolving regulatory CMC guidance in the AAV gene therapy field

Scalable production in single-use bioreactors

Chromatographic modalities, buffer selection and other considerations for enrichment of AAV product

De-risking lentiviral vector production using a robust, scalable, suspension-based platform

Skip the hassle for AAV and AdV empty/full and titer data with Stunner

Development of anti-AAV assay for detection of pre-existing AAV immunity

Analyzing full and empty AAV capsid ratio in less than 5 minutes

Large-scale genome editing of primary human natural killer (NK) cells: A quest toward manufacture of clinically relevant CAR NK cells

High-throughput process & analytical platforms to accelerate gene therapy scale-up

Environmental monitoring: optimizing microbial control in cell and gene therapy workflows

Manufacturing and testing a clinical-grade AAV vector: from concept to clinic

Future-proof your AAV process with a complete producer cell line – just induce and grow